DAFA-H 10 mg Tablets

DAFA-H 10 mg Tablets
Generic Name:
Dapagliflozin 10 mg
Therapeutic Group:
Antidiabetic Agents
Drug Category:
SGLT2 Inhibitor (Sodium-Glucose Co-Transporter 2 Inhibitor)
Content / Composition:
Each film-coated tablet contains:
Dapagliflozin …………………………… 10 mg
Excipients ……………………………… q.s.
Indications:
DAFA-H is indicated for:
Type 2 Diabetes Mellitus
Improvement of glycemic control as monotherapy or combination therapy
Reduction of cardiovascular events in high-risk patients
Chronic kidney disease (CKD) management in diabetic patients
Adjunct to diet and exercise
Dosage:
Recommended dose: 10 mg once daily
Taken once daily at any time of the day
Can be taken with or without food
Dose adjustment may be required based on renal function
As directed by the physician
Contraindications:
Hypersensitivity to dapagliflozin or any component
Type 1 Diabetes Mellitus
Diabetic ketoacidosis
Severe renal impairment (eGFR <30 mL/min/1.73 m²)
Pregnancy and breastfeeding
Administration:
Oral administration with sufficient water
Maintain adequate hydration
Preferably taken at the same time daily
Drug Interactions:
Diuretics: Increased risk of dehydration and hypotension
Insulin or sulfonylureas: Increased risk of hypoglycemia
Antihypertensives: May enhance hypotensive effect
Monitor renal function when used with nephrotoxic drugs
Compatibility:
Can be safely combined with metformin, DPP-4 inhibitors, insulin, and other antidiabetic agents
Suitable for long-term diabetes management strategies
Stability / Storage:
Store below 25°C
Protect from moisture, light, and heat
Keep out of reach of children
Precautions:
Risk of dehydration and hypotension
Monitor kidney function before and during treatment
Increased risk of urinary and genital infections
Rare risk of diabetic ketoacidosis (even with normal glucose levels)
Use with caution in elderly patients
Side Effects:
Common:
Increased urination
Genital fungal infections
Urinary tract infections
Thirst
Uncommon:
Dizziness
Hypotension
Dehydration
Serious (Rare):
Diabetic ketoacidosis
Acute kidney injury
Severe urinary/genital infections
Clinical Note:
DAFA-H (Dapagliflozin) is an advanced SGLT2 inhibitor that not only improves glycemic control but also provides significant cardiovascular and renal protection benefits. It is widely recommended in modern diabetes management guidelines.